PROX1 and neoplasm: Importantly, the pre–AR inhibitor treatment ARPC tumor (2623-1) and post–AR inhibitor treatment DNPC tumor (2623-2) (Supplemental Figure 1C) were taken from the same patient, demonstrating that preexisting PROX1-high cells were not present in the pretreatment ARPC tumor we examined.